|Day Low/High||66.42 / 68.86|
|52 Wk Low/High||60.23 / 118.32|
Incyte Corporation (Nasdaq:INCY) today announced positive results from its randomized, dose-ranging, vehicle- and active-controlled Phase 2b study evaluating ruxolitinib cream in patients with atopic dermatitis (AD) who are candidates for topical therapy.
Incyte Corporation (NASDAQ:INCY) and Foundation Medicine, Inc., today announced that the companies have entered into an agreement for the development, regulatory support and commercialization of companion diagnostics (CDx), with an initial focus on CDx...
Incyte Corporation (Nasdaq:INCY) today announced that David Gryska, Executive Vice President and Chief Financial Officer, intends to retire at the end of 2018 and that Incyte has launched a search for his replacement.
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the Morgan Stanley 16 th Annual Global Healthcare Conference on Thursday, September 13, 2018 at 10:00 am EDT in New York.
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Incyte Corporation has taken over the #197 spot from Total System Services, Inc. , according to ETF Channel.
Incyte Corporation (Nasdaq:INCY) today reports 2018 second quarter financial results, highlighting strong growth in total product-related revenue and providing a status update on the Company's development portfolio.
INDIANAPOLIS, July 19, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that results of a global systemic lupus erythematosus (SLE) Phase 2 study for baricitinib were published by The Lancet.
Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its second quarter 2018 financial results conference call and webcast for 8:00 a.
On the search for promising stocks, give these 10 names from Goldman Sachs a consideration.
Incyte Corporation (Nasdaq:INCY) will host an investor and analyst event in New York City today to provide a comprehensive update on the Company's growth opportunities and late-stage development portfolio.
Incyte Corporation (Nasdaq:INCY) today announced positive topline results from its ongoing pivotal Phase 2 REACH1 trial evaluating ruxolitinib (Jakafi ®) in combination with corticosteroids for the treatment of patients with steroid-refractory acute...
The most recent short interest data has been released for the 05/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Highlights include new Phase 2 data for baricitinib in systemic lupus erythematosus
NEW YORK, June 5, 2018 /PRNewswire/ -- ARMO BioSciences, Inc. (ARMO) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed sale of ARMO to Eli Lilly, whereby shareholders will receive $50.
The approval of OLUMIANT is based on the Phase 3 clinical trial program that demonstrated efficacy for difficult to treat patients1
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: Goldman Sachs 39 th Annual Global Healthcare Conference on Tuesday, June 12, 2018 at 2:40 pm (PDT) / 5:40 pm (EDT) in...
Jim Cramer weighs in on Sirius XM Radio, Teva Pharmaceuticals, iQIYI, Blue Apron, Shopify, Incyte, E*Trade Financial and more.
Jim Cramer tells investors to keep their eyes open for companies making changes -- that's what's being rewarded.
Incyte Corporation (Nasdaq:INCY) today reports 2018 first-quarter financial results, highlighting strong growth in total product-related revenue and providing a status update on the Company's development portfolio.
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018 at 8:40 am PDT in Las Vegas.
Incyte Corporation (Nasdaq:INCY) announces that multiple abstracts from its research and development portfolio will be presented at the upcoming 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois from June 1-5, 2018.
Lilly's chairman and CEO David Ricks said in an earnings call that he was confident in the risk-benefit profile for both proposed doses of the new drug.
China's response to U.S. tariffs has markets tanking Friday, eating into the gains from a mostly positive week.
Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that an external Data Monitoring Committee (eDMC) review of the pivotal Phase 3 ECHO-301/KEYNOTE-252...
Incyte Corporation (Nasdaq:INCY) announces that 15 abstracts from its research and development portfolio will be presented at the upcoming 2018 American Association for Cancer Research (AACR) annual meeting in Chicago,...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.